Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Apr;89(4):487-497.
doi: 10.1007/s00280-022-04406-6. Epub 2022 Mar 5.

Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors

Nusayba A Bagegni  1 , Haeseong Park  1 , Katlyn Kraft  1 , Maura O-Toole  1 , Feng Gao  2 , Saiama N Waqar  1 , Lee Ratner  1 , Daniel Morgensztern  1 , Siddhartha Devarakonda  1 , Manik Amin  3 , Maria Q Baggstrom  1 , Chris Liang  4 , Giovanni Selvaggi  4 , Andrea Wang-Gillam  5
Affiliations
Clinical Trial

Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors

Nusayba A Bagegni et al. Cancer Chemother Pharmacol. 2022 Apr.

Abstract

Purpose: Vorolanib is a multi-target tyrosine kinase inhibitor with anti-angiogenic properties. This study aimed to evaluate the tolerability, safety and efficacy of vorolanib when added to checkpoint inhibitors (CPIs) in patients with advanced solid tumors.

Methods: We conducted a phase 1b study of vorolanib (300 or 400 mg orally once daily) plus pembrolizumab or nivolumab using a standard 3 + 3 design to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). The endpoints included safety, toxicity and objective response rate, according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).

Results: Sixteen patients (9 in pembrolizumab arm, 7 in nivolumab arm) with gastrointestinal or lung cancers were enrolled. All patients had at least 1 treatment-related adverse event (TRAE). The most common TRAEs across all cohorts were lymphopenia (n = 7), leukopenia (n = 5), fatigue (n = 5), and alanine aminotransferase elevation (n = 5); most toxicities were grade (G) 1-2. DLTs were reported in 3 patients at vorolanib 400 mg dose level, with G3 aspartate aminotransferase elevation, G3 rectal hemorrhage, and G3 rash. Of 13 total response-evaluable patients, 2 patients had confirmed partial responses (1 rectal squamous cell cancer and 1 small cell lung cancer). Two patients achieved prolonged stable disease. Vorolanib 300 mg daily was determined to be the RP2D for either pembrolizumab or nivolumab.

Conclusion: Combination vorolanib 300 mg orally once daily plus CPI appears to be a feasible regimen with manageable toxicity and promising efficacy in select tumor types. NCT03511222. Date of Registration: April 18, 2018.

Keywords: Advanced solid tumors; Checkpoint inhibitors; Immunotherapy; Nivolumab; Pembrolizumab; Vorolanib.

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. Saiama N. Waqar reports funding from SWOG-Clinical Trials Partnership for oversight of the Lung-MAP master protocol and sub-study activities as co-Principal Investigator, and serves as Chair of Data Safety Monitoring Board for a Hoosier Cancer Research Network study. On behalf of all authors, the corresponding author states that there is no conflict of interest.

Figures

Fig. 1
Fig. 1
Patient flow diagram
Fig. 2
Fig. 2
Radiographic tumor response and duration of therapy. Spider plot of best overall response. Radiographic response evaluated on the basis of Response Evaluation in Solid Tumors version 1.1 (RECIST v1.1). Each line represents one patient. The dotted lines at + 20% represent cutoffs for progressive disease and at − 30% represent cutoffs for partial response. X82 300 mg: Vorolanib 300 mg. X82 400 mg: Vorolanib 400 mg. Pembro: Pembrolizumab. Nivo: Nivolumab. HCC: Hepatocellular cancer. SCLC: Small cell lung cancer
See this image and copyright information in PMC

References

    1. Kato K, Shah MA, Enzinger P. KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol. 2019;15(10):1057–1066. doi: 10.2217/fon-2018-0609. - DOI - PubMed
    1. Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomized, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–771. doi: 10.1016/S0140-6736(21)01234-4. - DOI - PubMed
    1. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma (CheckMate 649): a randomized, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. doi: 10.1016/S0140-6736(21)00797-2. - DOI - PMC - PubMed
    1. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomized, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–1508. doi: 10.1016/S1470-2045(16)30498-3. - DOI - PMC - PubMed
    1. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–2092. doi: 10.1056/NEJMoa1801005. - DOI - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources